Glycolytic activity and in vitro effect of the pyruvate kinase activator AG-946 in red blood cells from low-risk myelodysplastic syndromes patients: A proof-of-concept study

被引：2

作者：

Fattizzo, Bruno ^{[1
,2
,6
]}

Vercellati, Cristina ^{[1
]}

Marcello, Anna ^{[1
]}

Patel, Parija ^{[3
]}

Wind-Rotolo, Megan ^{[3
]}

Pettine, Loredana ^{[1
]}

Bonanomi, Marcella ^{[4
,5
]}

Gaglio, Daniela ^{[4
,5
]}

Bortolotti, Marta ^{[1
,2
]}

Leoni, Claudia ^{[1
,2
]}

Fermo, Elisa ^{[1
]}

Bianchi, Paola ^{[1
]}

Zaninoni, Anna ^{[1
]}

Passamonti, Francesco ^{[1
,2
]}

Barcellini, Wilma ^{[1
]}

机构：

[1] Fdn IRCCS Ca Granda Osped Maggiore Policlin, SC Ematol, SS Fisiopatol Anemie, Milan, Italy

[2] Univ Milan, Dept Oncol & Hematooncol, Milan, Italy

[3] Agios Pharmaceut Inc, Cambridge, MA USA

[4] Italian Natl Res Council IBFM CNR, Inst Mol Bioimaging & Physiol, Segrate, MI, Italy

[5] ISBE Elixir European Infrastruct Syst Biol, Milan, Italy

[6] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Via F Sforza 35, I-20100 Milan, Italy

来源：

AMERICAN JOURNAL OF HEMATOLOGY | 2024年 / 99卷 / 06期

关键词：

D O I：

10.1002/ajh.27300

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1201 / 1204

页数：4

共 8 条

[1] Biochemical and Metabolomic Analysis of Glycolytic Activity in Red Blood Cells from LowRisk Myelodysplastic Syndromes (LR-MDS) Patients and in-Vitro Effect of the Pyruvate Kinase Activator AG-946
Fattizzo, Bruno
Vercellati, Cristina
Marcello, Anna
Patel, Parija
Wind-Rotolo, Megan
Pettine, Loredana
Bonanomi, Marcella
Gaglio, Daniela
Leoni, Claudia
Fermo, Elisa
Bianchi, Paola
Zaninoni, Anna
Barcellini, Wilma
BLOOD, 2023, 142
[2] The Pyruvate Kinase (PK) Activator AG-946 Improves PK Properties and Red Blood Cell (RBC) Characteristics upon Ex Vivo treatment of RBCs from Patients with Myelodysplastic Syndromes
De Wilde, Jonathan R. A.
Ruiter, Titine J. J.
van Oirschot, Brigitte A.
Jans, Judith J. M.
Dang, Lenny
Wind-Rotolo, Megan
Thielen, Noortje
van Solinge, Wouter W.
van Rhenen, Anna
van Wijk, Richard
Rab, Minke A. E.
BLOOD, 2023, 142
[3] Pharmacodynamic Effects of AG-946, a Highly Potent Next-Generation Activator of Pyruvate Kinase, in Ex Vivo Treatment of Red Blood Cells from Sickle Cell Disease Patients
Rab, Minke A. E.
Van Dijk, Myrthe J.
Bos, Jennifer
van Oirschot, Brigitte A.
Gerrits, Johan
Kosinski, Penelope A.
Kung, Charles
Jans, Judith J. M.
Van Beers, Eduard J.
Dang, Lenny
van Wijk, Richard
BLOOD, 2021, 138
[4] AG-348 enhances pyruvate kinase activity in red blood cells from patients with pyruvate kinase deficiency
Kung, Charles
Hixon, Jeff
Kosinski, Penelope A.
Cianchetta, Giovanni
Histen, Gavin
Chen, Yue
Hill, Collin
Gross, Stefan
Si, Yaguang
Johnson, Kendall
DeLaBarre, Byron
Luo, Zhiyong
Gu, Zhiwei
Yao, Gui
Tang, Huachun
Fang, Cheng
Xu, Yingxia
Lv, Xiaobing
Biller, Scott
Su, Shin-San Michael
Yang, Hua
Popovici-Muller, Janeta
Salituro, Francesco
Silverman, Lee
Dang, Lenny
BLOOD, 2017, 130 (11) : 1347 - 1356
[5] Evaluation of Red Blood Cell Metabolism in Patients with Low-Risk Myelodysplastic Syndrome (LR-MDS): A Proof-ofConcept Study
Fattizzo, Bruno
Vercellati, Cristina
Marcello, Anna
Bortolotti, Marta
Zaninoni, Anna
Fermo, Elisa
Bianchi, Paola
Barcellini, Wilma
BLOOD, 2022, 140 : 4016 - 4017
[6] EX VIVO TREATMENT OF RED BLOOD CELLS FROM 15 PYRUVATE KINASE (PK)-DEFICIENT PATIENTS WITH AG-348, AN ALLOSTERIC ACTIVATOR OF PK-R, INCREASES ENZYMATIC ACTIVITY, PROTEIN STABILITY AND ATP LEVELS.
van Oirschot, B.
Kosinski, P. A.
Hixon, J.
Johnson, K.
Chubukov, V.
Dang, L.
Pasterkamp, G.
van Straaten, S.
Kung, C.
van Wijk, R.
HAEMATOLOGICA, 2017, 102 : 241 - 242
[7] Hematologic Improvement-Neutrophil and-Platelet in the MEDALIST Trial: Multilineage Data From a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients With Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes With Ring Sideroblasts Who Require Red Blood Cell Transfusions
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02)
[8] Hematologic Improvement-Neutrophil and -Platelet in the MEDALIST Trial: Multilineage Data from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions
Garcia-Manero, Guillermo
Mufti, Ghulam J.
Fenaux, Pierre
Buckstein, Rena
Santini, Valeria
Diez-Campelo, Maria
Finelli, Carlo
Cazzola, Mario
Ilhan, Osman
Sekeres, Mikkael A.
List, Alan F.
Laadem, Abderrahmane
Ito, Rodrigo
Zhang, Jennie
Rampersad, Anita
Sinsimer, Daniel
Linde, Peter G.
Platzbecker, Uwe
Komrokji, Rami
BLOOD, 2019, 134

← 1 →